Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.32 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25230650 | 0.98 | KDM1A (0.32) | KDM1AKCNH2KDM1BLOXL2 | |
| SCHEMBL23114162 | 0.84 | TAAR1 (0.44) | — | |
| SCHEMBL24357643 | 0.81 | — | — | |
| SCHEMBL12551771 | 0.81 | GABRA1 (0.38) | — | |
| SCHEMBL6706730 | 0.80 | TAAR1 (0.32) | — | |
| SCHEMBL855788 | 0.80 | KDM1A (0.44) | KDM1AKCNH2KDM1BLOXL2 | |
| SCHEMBL25299078 | 0.79 | — | — | |
| SCHEMBL31414091 | 0.79 | — | — | |
| SCHEMBL24357772 | 0.79 | PDCD1 (0.37) | — | |
| SCHEMBL4621794 | 0.78 | LOXL2 (0.38) | LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570631-B2 | Substituted N-(4-(pyrimidin and pyridin-4-yl)benzylcarboxamides and its use for treating disorders responsive to inhibition of Btk | BIOGEN MA INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4051680-B1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12391697-B2 | Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-12240838-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20240327380-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2024-10-03 | — | — | US | disclosed |
| EP-3793994-B1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3793994-B1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4192587-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2023086521-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230121818-A1 | BTK INHIBITORS | BIOGEN MA INC. | 2023-04-20 | — | — | US | disclosed |
| US-20220259194-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2022-08-18 | — | — | US | disclosed |
| EP-3969124-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| WO-2022032019-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2021133894-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021087112-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021087112-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| EP-3793994-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-10899753-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2021-01-26 | — | — | US | disclosed |
| WO-2020232330-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020232330-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240838-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | KDM1A 1524/4885KCNH2 2057/4885KDM1B 1454/4885 |
| US-20230121818-A1 | BTK INHIBITORS | BTK, SYK, LYN | KDM1A 1023/4885KCNH2 1393/4885KDM1B 848/4885 |
| US-12570631-B2 | Substituted N-(4-(pyrimidin and pyridin-4-yl)benzylcarboxamides and its use for treating disorders responsive to inhibition of Btk | BTK, LYN, SYK | KDM1A 1956/4885KCNH2 612/4885KDM1B 1299/4885 |
| US-20240327380-A1 | BTK INHIBITORS | BTK, SYK, LYN | KDM1A 932/4885KCNH2 1356/4885KDM1B 894/4885 |
| US-10899753-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | KDM1A 1524/4885KCNH2 2057/4885KDM1B 1454/4885 |
| US-12391697-B2 | Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase | ABL1, CDK1, CDK2 | KDM1A 774/4885KCNH2 1305/4885KDM1B 674/4885 |
| US-20220259194-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | KDM1A 1524/4885KCNH2 2057/4885KDM1B 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.